

List of required documents to be submitted to GA of CT at Bio Inn-EDA for Bioequivalence Studies

Year 2025

Code: EDREX.NP.Bioinn.12

Version No.2

Issue Date: 24 Sep. 2025 Effective date: 16 Nov. 2025

Version /year: 2/2025

Central Administration of Biological and Innovative products and clinical studies General Administration of clinical Trials



- **1- Signed, stamped and dated official delegation letter** from the Bioequivalence Center to the representative person who will submit the documents and deal with Bio-Inn EDA.
- **2- Detailed Study protocol** with version number and date. The protocol should be signed and dated by the sponsor and the PI.
- **3- Case Report Form,** with its version and date. A printed or electronic document designed to record all the protocol required information to be reported to the sponsor on each trial subject.
- **4-** The finalized IRB approved Informed Consent Form (ICF), with its version and date.
- 5- Evidence document of accreditation of BE center by any accrediting entities (if available)
- **6- Institutional Review Board approval including list of reviewed documents.** The IRB approval must be valid and with clear expiry date.
- 7- Questions raised by the IRB to the applicant regarding the submitted protocol and their answers (if available)
- 8- License of the Bioequivalence Center
- **9- Valid insurance certificate,** to document that compensation to subject(s) for trial-related injury will be available. It should include the name of the insured entity, and the number of involved subjects and the related annexes. The insurance company must be a local one or an international company that have a legal representative in the Arab Republic of Egypt.
- 10- Updated Curriculum Vitae and GCP Training certificate evidencing the qualifications of the Principal Investigator and Co-Investigator and other site staff to document their eligibility to conduct the clinical trial and/or to provide medical supervision of subjects.
- 11- Principal Investigator & Co-Investigator(s) conflict of interest and financial disclosure with the study sponsor.